This page shows the latest Balversa news and features for those working in and with pharma, biotech and healthcare.
Astex subsequently entered into a drug discovery collaboration and licence agreement on FGFR inhibitors with Janssen – a pharmaceutical arm of Johnson &Johnson – which resulted in the identification of Balversa (erdafitinib), approved
J&J has a strong presence in the bladder cancer area, with its targeted bladder cancer drug Balversa (erdafitinib) gaining approval in the US earlier this year. ... With Balversa, a 99-patient study demonstrated a 40% overall response rate, 3% complete
Other FGFR inhibitors being tested for bile duct cancer include Johnson &Johnson’s Balversa (erdafitinib) – approved earlier this year for FGFR-mutated bladder cancer – as well as Bridge Bio’s infigratinib.
Balversa is first FGFR inhibitor. Johnson &Johnson’s highly anticipated bladder cancer drug Balversa has been approved in the US, becoming the first personalised treatment targeting a certain type of genetic ... We recognise the significant unmet need
More from news
Approximately 2 fully matching, plus 2 partially matching documents found.
We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...